A new study in The Lancet Gastroenterology & Hepatology reveals that hepatitis B drugs are vastly underused, despite being safe and effective. Experts say early treatment can prevent liver damage, cancer, and deaths. With less than 3% of infected people treated, researchers urge broader access to save millions of lives globally.